EU/3/16/1745
Table of contents
About
On 14 October 2016, orphan designation (EU/3/16/1745) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 (also known as CTL019) for the treatment of diffuse large B-cell lymphoma.
This medicine is now known as tisagenlecleucel.
The sponsorship was transferred to Novartis Europharm Limited, Ireland, in May 2018.
Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 for treatment of diffuse large B-cell lymphoma has been authorised in the EU as Kymriah since 23 August 2018.
Key facts
Active substance |
Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 (tisagenlecleucel)
|
Disease / condition |
Treatment of diffuse large B-cell lymphoma
|
Date of first decision |
14/10/2016
|
Outcome |
Positive
|
EU designation number |
EU/3/16/1745
|
Review of designation
The Committee for Orphan Medicinal Products reviewed the orphan designation of Kymriah at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.
More information is available in the
orphan medicine assessment report
.
Sponsor's contact details
Novartis Europharm Limited
Vista Building
Elm Park
Merrion Road
Dublin 4 D04 A9N6
Tel. +41 613 241 111
E-mail: orphan.enquiries@novartis.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.